



Davos Alzheimer's Collaborative: Global Vision for Global Cohorts

Rhoda Au, Ph.D.






Achieving Global Parity









Build technology-enabled solutions that bypass existing infrastructure limitations


Empower low resourced cohorts to contribute equally to that of high resourced ones

Foundational Data Collection Priorities





Blood Samples for GWAS



Digital Phenotyping



Metabolomics & Metagenomics

The Value of Blood



Genomics

- Generating polygenic risk scores (GWAS)
- Identifying therapeutic targets

AD Blood Biomarker Data

- Aβ40
- Aβ42
- GFAP
- Neurofilament light
- pTau 181

Exposome Data

- Education
- Metals
- Air pollution
- etc

Core Clinical Data

- Glucose
- Cholesterol
- Lipids
- etc.

Repository for Future Profiling

 Future profiling as science progresses

The Value of Digital



Low barriers to usage

- Can be selfadministered or through minimally trained staff
- Smartphone apps make global reach possible
- Enable options for passive monitoring
- Non-invasive (compared with phlebotomy and CSF extraction)

Low costs

- Low cost barriers to entry
- Easy upgrade methods
- High ROI because is a non-diluted resource

Fast

- Some results can be obtained in real time
- New applications/ upgrades can be immediately deployed virtually

Adaptive

- Precision
 personalization
 provides value to
 user
- Feedback loops create continually improving customization

Innovative

- Broad usage creates unique data resource
- Broad data access will drive new research and clinical directions
- Technology advancement pace will accelerate continuous improvement of digital assessment and monitoring tools as well as analytic methods

The Value of At Home Sample Kits



Low barriers to usage

- Can be collected in person's place of residence
- Kits have built in stabilization features at room temperature
- Leverage existing mail distribution channels

Low costs

- Less expensive compared to clinic-based sample collection methods
- Easy upgrade methods

Accurate

- Increased sampling capabilities
- Characterization of dynamic changes (metabolomics, proteomics)

Adaptive

- Precision tracking provides value to user
- Lifestyle intervention feedback loops allow precision intervention plans for maximal impact

Innovative

- More frequently collected data creates unique data resource
- Broad data access will accelerate pace of new drug targets
- Broad data access will also accelerate pace of nonpharmacologic interventions

The Value of Catalytic Challenges Analytic Strategy





Accelerate new technological advances



Biomarker identification/validation



Drug target development

- Examples of Types of Challenges
 - "Hands-free" complex phenotype harmonization
 - Invention of fluidic digital biomarkers
 - Audio recording automation
 - High accuracy speech-to-text transcription and diarization
 - Processing lower quality recordings similar to high quality recordings
- Leverage Challenge experts to run

 DAC-brand
- Example







Contact Information

Name: Rhoda Au

Email Address: rhodaau@bu.edu

Company Website:

https://www.davosalzheimerscollaborative.org/

Additional Contact Information: Philip Joung; pjoung@bu.edu